V

ViroGates A/S
CSE:VIRO

Watchlist Manager
ViroGates A/S
CSE:VIRO
Watchlist
Price: 14.2 DKK -3.73% Market Closed
Market Cap: 109.9m DKK

ViroGates A/S
Cash from Financing Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ViroGates A/S
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
V
ViroGates A/S
CSE:VIRO
Cash from Financing Activities
kr7.6m
CAGR 3-Years
-6%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
GN Store Nord A/S
CSE:GN
Cash from Financing Activities
-kr744m
CAGR 3-Years
N/A
CAGR 5-Years
-51%
CAGR 10-Years
-4%
Ambu A/S
CSE:AMBU B
Cash from Financing Activities
-kr153m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Demant A/S
CSE:DEMANT
Cash from Financing Activities
-kr2.3B
CAGR 3-Years
-36%
CAGR 5-Years
-57%
CAGR 10-Years
-17%
No Stocks Found

ViroGates A/S
Glance View

Market Cap
109.8m DKK
Industry
Health Care

ViroGates A/S develops and markets prognostic products for the healthcare sector. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.

VIRO Intrinsic Value
1.92 DKK
Overvaluation 86%
Intrinsic Value
Price
V

See Also

What is ViroGates A/S's Cash from Financing Activities?
Cash from Financing Activities
7.6m DKK

Based on the financial report for Sep 30, 2025, ViroGates A/S's Cash from Financing Activities amounts to 7.6m DKK.

What is ViroGates A/S's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-1%

Over the last year, the Cash from Financing Activities growth was -42%. The average annual Cash from Financing Activities growth rates for ViroGates A/S have been -6% over the past three years , -1% over the past five years .

Back to Top